Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Pediatr Infect Dis J. 2012 Apr;31(4):389-91. doi: 10.1097/INF.0b013e3182401c41.
We assessed the pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children while they were receiving nevirapine-containing fixed-dose combination tablets with rifampicin-based tuberculosis treatment and after discontinuation. The median age (range) was 9.7 (4.4-11.7) years. The nevirapine area under the concentration versus time curve from 0 to 12 hours and trough concentration with rifampicin were 85.3 (40.5-170.7) mg.h/mL and 6.4 (3.00-13.27) mg/mL, respectively, providing adequate exposure.
我们评估了 HIV 和结核分枝杆菌双重感染儿童在接受含利福平的结核治疗以及停止治疗后，奈韦拉平固定剂量复方片剂的药代动力学。中位年龄（范围）为 9.7（4.4-11.7）岁。奈韦拉平浓度-时间曲线下 0 至 12 小时面积和与利福平的谷浓度分别为 85.3（40.5-170.7）mg.h/mL 和 6.4（3.00-13.27）mg/mL，提供了充分的暴露。
